| Medical and Health Sciences | Lifetime | 334 | BE 6 | 99.99 |
| Medical and Health Sciences | 2021-2025 | 295 | BE 5 | 99.94 |
| Reproductive Medicine | Lifetime | 3 | BE 1 | 99.96 |
| Obstetrics and Gynecology | Lifetime | 12 | BE 1 | 99.87 |
| Oncology | Lifetime | 268 | BE 3 | 99.57 |
| Genetics | Lifetime | 913 | BE 11 | 97.75 |
| Cancer Research | Lifetime | 781 | BE 14 | 94.37 |
| Reproductive Medicine | 2021-2025 | 10 | BE 1 | 99.75 |
| Oncology | 2021-2025 | 71 | BE 2 | 99.61 |
| Obstetrics and Gynecology | 2021-2025 | 34 | BE 2 | 99.21 |
| Ovarian cancer diagnosis and treatment | Lifetime | 1 | BE 1 | 99.95 |
| Endometrial and Cervical Cancer Treatments | Lifetime | 1 | BE 1 | 99.96 |
| Intraperitoneal and Appendiceal Malignancies | Lifetime | 1 | BE 1 | 99.93 |
| PARP inhibition in cancer therapy | Lifetime | 3 | BE 1 | 99.80 |
| Uterine Myomas and Treatments | Lifetime | 45 | BE 6 | 99.50 |
| BRCA gene mutations in cancer | Lifetime | 67 | BE 1 | 99.26 |
| Renal cell carcinoma treatment | Lifetime | 110 | BE 1 | 99.32 |
| Endometriosis Research and Treatment | Lifetime | 104 | BE 6 | 99.12 |
| Cancer Mechanisms and Therapy | Lifetime | 80 | BE 1 | 98.98 |
| Estrogen and related hormone effects | Lifetime | 280 | BE 6 | 98.83 |
| Sarcoma Diagnosis and Treatment | Lifetime | 447 | BE 5 | 98.23 |
| Cancer, Lipids, and Metabolism | Lifetime | 414 | BE 5 | 98.40 |
| HER2/EGFR in Cancer Research | Lifetime | 378 | BE 12 | 98.37 |
| Cervical Cancer and HPV Research | Lifetime | 454 | BE 7 | 97.93 |
| Advanced Breast Cancer Therapies | Lifetime | 217 | BE 7 | 98.21 |
| Lymphoma Diagnosis and Treatment | Lifetime | 965 | BE 13 | 97.84 |
| Colorectal and Anal Carcinomas | Lifetime | 473 | BE 5 | 97.18 |
| Lung Cancer Research Studies | Lifetime | 790 | BE 9 | 97.43 |
| Angiogenesis and VEGF in Cancer | Lifetime | 786 | BE 14 | 95.76 |
| Cancer Risks and Factors | Lifetime | 977 | BE 7 | 93.89 |
| Gynecological conditions and treatments | Lifetime | 867 | BE 26 | 91.33 |
| Minimally Invasive Surgical Techniques | Lifetime | 560 | BE 9 | 90.70 |
| Gestational Trophoblastic Disease Studies | Lifetime | 703 | BE 8 | 83.06 |
| BRCA gene mutations in cancer | 2021-2025 | 5 | BE 1 | 99.55 |
| Ovarian cancer diagnosis and treatment | 2021-2025 | 7 | BE 1 | 99.89 |
| PARP inhibition in cancer therapy | 2021-2025 | 4 | BE 1 | 99.74 |
| Endometrial and Cervical Cancer Treatments | 2021-2025 | 9 | BE 1 | 99.80 |
| Intraperitoneal and Appendiceal Malignancies | 2021-2025 | 46 | BE 3 | 95.78 |
| HER2/EGFR in Cancer Research | 2021-2025 | 377 | BE 11 | 93.73 |
| Renal cell carcinoma treatment | 2021-2025 | 725 | BE 6 | 90.71 |
| Toxin Mechanisms and Immunotoxins | 2021-2025 | 147 | BE 2 | 82.92 |
| Cervical Cancer and HPV Research | 2021-2025 | 827 | BE 10 | 87.20 |
| DNA Repair Mechanisms | 2021-2025 | 646 | BE 3 | 82.76 |
| Cancer Mechanisms and Therapy | 2021-2025 | 624 | BE 1 | 77.42 |
| Uterine Myomas and Treatments | 2021-2025 | 968 | BE 18 | 78.28 |
| Gestational Trophoblastic Disease Studies | 2021-2025 | 613 | BE 7 | 37.28 |
